The Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: First Time Two-Year Results of the TAHOE Study

Authors

• Haaziq Ali
• Aamir Abdul Aziz
• Hannah Khan
• Huma Khan
• Zoha Khanani
• Talha Aziz
• Greggory Gahn
• David R P Almeida
• Mark Barakat
• Emmanuel Chang
• Giulia Corradetti
• Carl J. Danzig
• Jordan M. Graff
• Jeremy Wolfe, Corewell Health East
• SriniVas R. Sadda
• Arshad M. Khanani

Document Type

Conference Proceeding

Publication Date

6-2026

Publication Title

Investigative Ophthalmology and Visual Science

Abstract

Purpose : Faricimab was FDA-approved for diabetic macular edema (DME) in Jan 2022. This multi-center, retrospective study evaluates the safety and efficacy of faricimab in real-world patients diagnosed with DME.

Methods : This study investigates both treatment-naïve patients and patients switched to faricimab from other anti-VEGF agents. Data collected included demographics, treatment history, best-corrected visual acuity (BCVA), central subfield thickness (CST), and presence of subretinal or intraretinal fluid (SRF, IRF). Snellen visual acuity was converted to Early Treatment Diabetic Retinopathy Study (ETDRS) scoring. Improvements in visual acuity and CST are evaluated as averages. Improvements in retinal fluid are evaluated as a proportion. Safety is summarized.

Results : A total of 684 eyes across 442 patients were recorded. The average age was 65.5 years, 53.5% were male and 30.8% had switched from aflibercept. A total of 3,104 injections have been recorded. All eyes switched from any agent post three faricimab injections (n=335) had a BCVA increase of +1.25 letters (p=0.78) and a CST decrease of -24.70mm (p< 0.0001). Eyes switched from aflibercept post three faricimab injections (n=180) had a BCVA increase of +1.45 letters (p=0.09) and a CST decrease of -16.92mm (p=0.001). All treatment-naïve eyes post three faricimab injections (n=63) had a BCVA increase of +9.33 letters (p< 0.001) and a CST decrease of -92.23mm (p< 0.001).
All eyes switched from any agent post nine faricimab injections (n=101) had a BCVA increase of +4.00 letters (p=0.03) and a CST decrease of -56.69mm (p< 0.001). Eyes switched from aflibercept post nine faricimab injections (n=70) had a BCVA increase of +3.93 letters (p=0.04) and a CST decrease of -64.81mm (p< 0.001). All treatment-naïve eyes post nine faricimab injections (n=13) had a BCVA increase of +4.75 letters (p=0.21) and a CST decrease of -153.68mm (p< 0.001). Intraocular inflammation was noted at a rate of 0.08% per injection.

Conclusions : Faricimab has demonstrated efficacy via anatomic and visual parameters, in both treatment-naïve and previously treated patients, a demographic not studied in the trials leading to FDA-approval. Safety is comparable to current agents. Future results will continue to investigate the long-term safety, efficacy and durability of faricimab in real-world patients with DME. Latest data will be presented at ARVO 2026.

Volume

67

Issue

7

First Page

2860

Comments

Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 3-7, 2026, Denver, CO

Last Page

2860

Recommended Citation

Ali H, Aziz AA, Khan H, Khan H, Khanani Z, Azia T, et al. [Wolfe J]. The real-world efficacy and safety of faricimab in diabetic macular edema: first time two-year results of the TAHOE study. Invest Ophthalmol Vis Sci. 2026 Jun;67(7):2860.